Eliminating Creatine Kinase-Myocardial Band Testing in Suspected Acute Coronary Syndrome: A Value-Based Quality...

Area of Science:

• Cardiology
• Clinical Biochemistry
• Health Economics

Background:

• Cardiac biomarker testing is prevalent in US emergency departments, with nearly 30 million annual visits.
• Cardiac troponin is the preferred biomarker due to its high specificity and sensitivity for myocardial injury, as recommended by major cardiology societies.
• Despite recommendations, creatine kinase-myocardial band (CK-MB) testing persists in many healthcare settings.

Purpose of the Study:

• To evaluate the impact of eliminating routine CK-MB testing on patient care quality and healthcare costs.
• To support the transition from CK-MB to more specific cardiac biomarkers like troponin.

Main Methods:

• Review of patient safety outcomes data from academic medical centers that have discontinued routine CK-MB testing.
• Analysis of healthcare cost savings associated with eliminating non-essential laboratory tests.
• Comparison of patient care quality metrics before and after the intervention.

Main Results:

• Interventions to eliminate routine CK-MB testing have been successfully implemented in several academic medical centers.
• Published data indicate no adverse effects on patient care quality following the discontinuation of CK-MB tests.
• Significant healthcare cost savings are achievable by removing redundant diagnostic tests.

Conclusions:

• Discontinuing routine CK-MB testing is a viable strategy to reduce healthcare expenditures.
• Eliminating tests without incremental diagnostic value, like CK-MB, can improve overall patient care by focusing resources on more effective biomarkers.
• The shift towards cardiac troponin testing aligns with clinical guidelines and enhances diagnostic accuracy for myocardial injury.